NCT01477281

Study to Evaluate the Efficacy and Tolerability of Venaflon Use in Reducing the Symptoms Caused by Chronic Venous Insufficiency When Compared With Daflon

A Clinical Multicenter, Phase III, Prospective, Randomized, Double-blind, Comparative Study to Evaluate the Efficacy and Tolerability of Venaflon Use in Reducing the Symptoms Caused by Chronic Venous Insufficiency When Compared With Daflon

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 82 (estimated)
• Sponsor: Laboratório Teuto Brasileiro S/A · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The objective is to evaluate the effectiveness of the safety of Daflon in decreasing symptoms resulting from chronic venous insufficiency when compared with Daflon.

Detailed description

"A clinical multicenter, phase III, prospective, randomized, double-blind, comparative study to evaluate the efficacy and tolerability of Venaflon use in reducing the symptoms caused by chronic venous insufficiency when compared with Daflon."

Conditions

• Chronic Venous Insufficiency
• Disease

Interventions

Type	Name	Description
DRUG	Daflon	Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
DRUG	Venaflon (Diosmin and Hesperidin)	Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).

Timeline

• Start date: 2012-02-01
• Primary completion: 2012-07-01
• Completion: 2012-08-01
• First posted: 2011-11-22
• Last updated: 2011-11-22